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mate the impact of the new treatment on annual budgets
and health outcomes is shown. For chronic diseases, the
impact of a new treatment on annual budget and health
outcomes may change over the first few years, until a new
steady state is reached. How these estimates vary with
different assumptions about the extent of use of the new
treatment is shown. A method for generating these esti-
mates using a model developed to estimate the budget
and health outcome impacts of new HIV treatments for
state- or federally-funded programs is illustrated. Popula-
tion estimates allow healthcare decision-makers to evalu-
ate the impact on their budgets and patient health of 1)
providing the new treatment to their patients, and 2)
ensuring that they have sufficient funds available. This
workshop will be of value both to industry pharmaco-
economists and national and/or local healthcare decision-
makers. How to generate analyses of economic and health
outcomes in a population format that is likely to be of
value for new treatment decisions will be shown.
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Handling survival data in cost-effectiveness (CE) studies
generally implies an assessment of the survival data pre-
sented in clinical trials (measured survival), together with a
long-term prediction of life expectancy for the same pa-
tients (predicted survival). Because different methods are
needed to manage the data of measured survival and of
predicted survival, this workshop will present an overview
of these methods and discuss their relative advantages and
disadvantages. 1. Measured survival: When a single clini-
cal trial is the source of the survival information, tradi-
tional methods for constructing survival curves can be uti-
lized in CE studies. When two or more clinical trials are
available, combining the data requires a survival meta-
analysis. Although the methodology of survival meta-anal-
ysis is still under development, some techniques in this area
have adequately been tested and can therefore be proposed
for general use. 2. Predicted survival: Traditional life-
expectancy calculations remain the mainstay for predicting
survival in healthy subjects or in “cured” patients. Specific
methods, however, are needed for correcting normal life
expectancy predictions on the basis of the presence of a
disease condition. The Gompertz extrapolation technique
can be used for conditions where the chance of cure is min-
imal. Furthermore, other methods have recently been pro-
posed for combining the clinical evidence of a specific
survival pattern with the assignment of a normal life ex-
pectancy to “long term survivors.” This workshop is de-
signed to provide an overview of the foregoing methods; to
report on their use in clinical and economic evaluation;
and to present detailed examples of their application. It is
expected that workshop attendees will be primarily re-
searchers and analysts concerned with clinical and eco-
nomic evaluation, particularly where multi-center collabo-
ration is involved.
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Society’s perspective of costs and benefits of healthcare
programs has been well established in theory and method-
ology of outcomes research. Far less rigorously examined
are issues from the perspective of the payers. For rehabili-
tation programs in Germany, the perspective of Social Old
Age Insurance Funds (SOAIF) is of particular importance.
For the workforce, SOAIF finances most rehabilitative in-
terventions; they finance invalidity pensions in cases where
their insured can no longer participate in the workforce;
and rehabilitation programs are designed to avoid invalid-
ity. In the workshop, theoretical and methodological issues
of a payer’s perspective in general, and of SOAIF in partic-
ular, are discussed. Four perspectives of SOAIF can be dis-
tinguished: 1) minimizing SOAIF’s expenditure—this re-
quires financing rehabilitative intervention in case it can be
assumed that the expenditure for invalidity pensions saved
through an intervention exceeds the expenditure for the in-
tervention itself; 2) minimizing costs and cases of invalidity
according to the (German) social code on rehabilitation—
here the costs of interventions are not considered; 3) maxi-
mizing a social welfare function—as part of social insur-
ance and the welfare state arrangements, SOAIF could be
required to maximize a social welfare function, which
could be identical to society’s perspective; and 4) maximiz-
ing the utility function of SOAIF’s bureaucrats—according
to this perspective, as many rehabilitation interventions
will be produced as is necessary to maximize power, pres-
tige and income of the functionaries of the pension funds.
Consequences for study designs are discussed.
W14
DESIGNING AN INTERNATIONAL PIGGYBACK 
STUDY: PROVIDING THE FOUNDATION
Crawford B1, Evans C2
1MAPI Values, Boston, MA, US; 2Astra Pharmaceuticals, 
Westborough, MA, US
Pharmacoeconomic and quality of life analyses are becom-
ing more familiar and hence more important to marketing
and reimbursement. The use of piggyback studies as an an-
